glp 1 receptor agonist moa Glucagon-like peptide-1 receptor: mechanisms and advances in therapy GLP1 Receptor Agonists—Effects beyond Obesity

Kidney360 2 , 254262 (2021)

Effects on Body Weight A recent update to the American Heart Association/American Diabetes Association (AHA/ADA) guidelines on cardiovascular disease (CVD) prevention in adults with type 2 diabetes highlights weight management as a key component and suggests that health care providers consider using antihyperglycemic drugs that produce weight loss, including the GLP-1 receptor agonists (22)

miRNA-122-5p has been shown to inhibit forkhead box O3 (FOXO3)

Med (Baltim)

Despite these few reports, liraglutide seems to be a safe drug in terms of kidney function

Based on the PIONEER programme, oral semaglutide has been licensed for people with T2D and the 14 mg dose, leads to HbA1c improvement up to 1.4% and WL up to 4.4 kg [20]